Zacks Investment Research downgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a buy rating to a hold rating in a research note released on Tuesday, Zacks.com reports.

According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “

DMAC has been the subject of a number of other reports. Craig Hallum increased their price target on shares of DiaMedica Therapeutics from $9.00 to $11.00 and gave the stock a buy rating in a research note on Thursday, June 20th. Dougherty & Co reissued a buy rating on shares of Iteris in a research note on Tuesday, April 30th.

DMAC stock traded down $0.14 during trading on Tuesday, reaching $3.77. The company had a trading volume of 21,178 shares, compared to its average volume of 272,059. DiaMedica Therapeutics has a 52 week low of $2.46 and a 52 week high of $5.93. The business’s 50 day moving average price is $3.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.49 and a quick ratio of 10.49.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.05). On average, equities research analysts expect that DiaMedica Therapeutics will post -0.85 earnings per share for the current fiscal year.

In other DiaMedica Therapeutics news, Director Richard D. Pilnik acquired 19,000 shares of the business’s stock in a transaction on Friday, May 31st. The shares were acquired at an average price of $2.80 per share, for a total transaction of $53,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.80% of the stock is currently owned by corporate insiders.

An institutional investor recently bought a new position in DiaMedica Therapeutics stock. Worth Venture Partners LLC acquired a new position in DiaMedica Therapeutics Inc (NASDAQ:DMAC) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 129,863 shares of the company’s stock, valued at approximately $377,000. Worth Venture Partners LLC owned 1.09% of DiaMedica Therapeutics as of its most recent filing with the Securities & Exchange Commission. 8.48% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Recommended Story: Why is cost of goods sold important?

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMAC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.